Blue Shield of California helped create CivicaScript in 2020 to make prescription drugs more affordable for everyone. Today’s announcement of pen-administered insulin for just $45 for a set of five pens marks a significant milestone in that mission.
Beginning January 1, 2026, this low-cost prescription drug will be available to members enrolled in Blue Shield’s commercial health plans. This milestone underscores Blue Shield’s commitment to transforming the pharmacy supply chain to ensure equitable access, lower costs and greater price transparency.
Relevant articles:
- SB 41: California Leads the Nation With New Prescription Drug Cost Reform (October 14, 2025)
- Blue Shield of California Launches First-in-the-Nation Digital Experience to Improve Medication Choice and Transparency (August 6, 2025)
- Blue Shield of California Slashes Cost of World’s Best-Selling Drug (October 1, 2024)
- Blue Shield of California Joins White House Panel on Pharmacy and Drug Cost Reforms Needed for All Americans (March 11, 2024)
- Blue Shield of California Unveils First-of-its-Kind Model to Transform Prescription Drug Care; Save up to $500 Million on Medications Annually (August 17, 2023)
